secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001628280-25-035847
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi
--------------------------------------------------------------------------------

- First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).
- Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.
- $75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.
- Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.
- VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/0001628280-25-035847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/vir-20250724.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-035847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer